LUCELBA Trademark

Trademark Overview

On Monday, October 25, 2010, a trademark application was filed for LUCELBA with the United States Patent and Trademark Office. The USPTO has given the LUCELBA trademark a serial number of 79090561. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Sunday, October 25, 2020. This trademark is owned by NOVARTIS AG. The LUCELBA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention or treatment of diseases and disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system and the genitourinary system, for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and transplantation of tissues and organs, in ophthalmology and gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular diseases and disorders, for the treatment of bacteria-based diseases and disorders, autoimmune diseases and disorders, kidney diseases and disorders, diabetes; antifungal, anti-infective, antiviral, and antibiotic preparations
lucelba

General Information

Serial Number79090561
Word MarkLUCELBA
Filing DateMonday, October 25, 2010
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateSunday, October 25, 2020
Registration Number3991944
Registration DateTuesday, July 12, 2011
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2011

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention or treatment of diseases and disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system and the genitourinary system, for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and transplantation of tissues and organs, in ophthalmology and gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular diseases and disorders, for the treatment of bacteria-based diseases and disorders, autoimmune diseases and disorders, kidney diseases and disorders, diabetes; antifungal, anti-infective, antiviral, and antibiotic preparations
Translation of Words in MarkThe wording "LUCELBA" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, February 16, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovartis AG
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCH
Party NameNOVARTIS AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCH
Party NameNOVARTIS AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCH

Trademark Events

Event DateEvent Description
Sunday, November 7, 2021NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Sunday, November 7, 2021DEATH OF INTERNATIONAL REGISTRATION
Saturday, December 15, 2018TOTAL INVALIDATION PROCESSED BY THE IB
Saturday, October 27, 2018TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, October 27, 2018INVALIDATION PROCESSED
Tuesday, October 16, 2018TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, February 16, 2018CANCELLED SECTION 71
Saturday, April 13, 2013NEW REPRESENTATIVE AT IB RECEIVED
Saturday, February 23, 2013CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, January 6, 2012FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, December 16, 2011FINAL DISPOSITION NOTICE SENT TO IB
Friday, December 16, 2011FINAL DISPOSITION PROCESSED
Wednesday, October 12, 2011FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, July 12, 2011REGISTERED-PRINCIPAL REGISTER
Tuesday, April 26, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 26, 2011PUBLISHED FOR OPPOSITION
Wednesday, April 6, 2011NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, April 6, 2011NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Friday, March 18, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 16, 2011ASSIGNED TO LIE
Saturday, February 26, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, February 7, 2011EXAMINER'S AMENDMENT ENTERED
Monday, February 7, 2011NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, February 7, 2011EXAMINERS AMENDMENT E-MAILED
Monday, February 7, 2011EXAMINERS AMENDMENT -WRITTEN
Saturday, February 5, 2011REFUSAL PROCESSED BY IB
Wednesday, February 2, 2011ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 2, 2011TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 18, 2011NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, January 18, 2011REFUSAL PROCESSED BY MPU
Sunday, January 16, 2011NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, January 15, 2011NON-FINAL ACTION WRITTEN
Tuesday, January 11, 2011ASSIGNED TO EXAMINER
Saturday, January 8, 2011APPLICATION FILING RECEIPT MAILED
Tuesday, January 4, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 3, 2011LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, December 30, 2010SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

lucelba system disorders diseases preparations treatment pharmaceutical prevention bacteria based ophthalmology